MIRXES-B (02629) experienced a significant surge of over 35% during afternoon trading. At the time of writing, the stock was up 32.99%, trading at HK$16.73, with a turnover of HK$498 million. The catalyst for this movement appears to be positive industry reception. The 23rd China International Medical Examination & Blood Transfusion Equipment and Reagents Expo (CACLP) concluded successfully on March 23rd at the Xiamen International Expo Center. MIRXES emerged as a highlight of the event, showcasing its leading miRNA detection technology and specialized early cancer screening solutions. Particular attention was drawn to its core product, MiRXES' GASTROClear™. It is reported that the product has completed prospective clinical validation involving nearly ten thousand individuals, demonstrating excellent detection performance. The product has already received approval in multiple countries and regions, including Singapore, China, and the European Union, addressing a significant gap in the market for non-invasive stomach cancer early screening. Furthermore, in late February, MIRXES announced the signing of a memorandum of understanding with Apollo Health and Lifestyle, a wholly-owned subsidiary of India's Apollo Group. The companies intend to jointly develop and commercialize advanced early cancer screening solutions in India and surrounding countries, with plans to establish a joint venture valued at no less than $50 million.